Company research / ARVN

Arvinas, Inc. (ARVN)

SEC name ARVINAS, INC. · CIK 0001655759 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Arvinas, Inc. reported revenue of $262.60M. Revenue fell 0.3% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $316.70M.

Key ratios (year ended 2025-12-31)

-45.1%
Operating margin
-30.8%
Net margin
-18.6%
Return on year-end equity
-0.3%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 10-Q (quarterly report) · 2026-08-04

Headquarters locality: New Haven · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Revenue$316.70M$262.60M$263.40M$78.50M$131.40M$53.60M$25.90M$43.00M$14.32M$7.58M
R&D Expense$238.80M$285.20M$348.20M$379.70M$315.00M$180.40M$108.40M$67.20M$45.19M$28.79M
Operating Income-$18.10M-$118.50M-$250.20M-$401.50M-$263.20M-$188.40M-$120.80M-$51.50M-$43.80M-$24.76M
Depreciation & Amortization$2.90M$3.00M$4.60M$4.80M$6.30M$4.80M$3.20M$1.60M$706.0K$347.4K
EBITDA-$15.20M-$115.50M-$245.60M-$396.70M-$256.90M-$183.60M-$117.60M-$49.90M-$43.10M-$24.41M
Net Income$9.30M-$80.80M-$198.90M-$367.30M-$282.50M-$191.00M-$119.30M-$70.30M-$41.48M-$24.05M
EPS (Diluted)n/a-$1.14-$2.77-$6.62-$5.31-$3.82-$3.02-$2.13n/an/a
Total Assets$675.10M$717.90M$1.09B$1.30B$1.27B$1.58B$717.40M$301.64M$199.28M$66.85M
Total Liabilities$112.90M$284.00M$529.70M$644.60M$703.90M$799.90M$75.20M$74.96M$62.61M$66.60M
Long-Term Debt$500.0K$600.0K$800.0K$1.00M$1.00M$1.00M$2.00M$2.00M$2.17Mn/a
Shareholders' Equity$562.20M$433.90M$561.70M$660.00M$564.90M$781.70M$642.20M$226.60M$136.67M-$61.23M
Cash & Equivalents$94.30M$142.90M$100.50M$311.70M$81.30M$108.30M$588.40M$9.21M$3.19M$30.91M
Operating Cash Flow-$207.00M-$273.80M-$259.30M-$347.80M-$273.50M$559.40M-$89.70M-$40.60M-$16.12M$5.11M
Capital Expenditures$1.80M$1.90M$1.80M$2.90M$6.80M$4.70M$6.40M$6.30M$2.83M$1.01M
Free Cash Flow-$208.80M-$275.70M-$261.10M-$350.70M-$280.30M$554.70M-$96.10M-$46.90M-$18.95M$4.10M
Share Repurchasesn/a$91.90M$0$0n/an/an/an/an/an/a
Shares Outstanding65.30M63.50M68.80M68.00M53.20M53.00M48.50M38.46M31.24Mn/a
Weighted Average Diluted Sharesn/a70.90M71.90M55.50M53.20M50.00M39.50M32.90Mn/an/a
EPS (Basic)n/a-$1.14-$2.77-$6.62-$5.31-$3.82-$3.02-$2.13n/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView